Celldex Therapeutics, Inc. (CLDX – Snapshot Report) announced the commencement of a phase I/II safety pilot and expansion study to evaluate Celldex’s varlilumab in combination with Bristol-Myers Squibb Company’s (BMY – Analyst Report) melanoma drug, Yervoy. Yervoy is approved for the treatment of unresectable or metastatic melanoma. The company intends to study the combination in patients suffering from stage III or IV metastatic melanoma.
MRV Research
BRAF Gene Mutation Associated With Different Melanoma Subtypes
A recent study published in the journal Melanoma Research and led by researchers at the National Cancer Center Hospital in Tokyo, Japan revealed an association between mutations in the BRAF gene and melanoma subtypes in Japanese patients. The study is entitled “BRAF V600 mutations and pathological features in Japanese melanoma patients.”
Personalized Melanoma Vaccines Marshal Immune Response
Personalized melanoma vaccines can be used to marshal a powerful immune response against unique mutations in patients’ tumors, according to early data in a first-in-people clinical trial at Washington University School of Medicine in St. Louis.
Celldex Therapeutics Announces Initiation of Phase 1/2 Study of Varlilumab in Combination with Ipilimumab and CDX-1401 in Metastatic Melanoma
Celldex Therapeutics, Inc. CLDX, +0.87% today announced the initiation of a Phase 1/2 safety pilot and expansion study examining the investigational combination of varlilumab and ipilimumab (Yervoy®; Bristol-Myers Squibb) in patients with Stage III or IV metastatic melanoma